FDA Reorg Elevates Generic Review Activities
This article was originally published in The Gold Sheet
In the two months since the enactment of the Generic Drug User Fee Act, FDA has announced a major recruitment from the brand sector to head its generic drug activities (Gregory Geba), approved one controversial transdermal generic (Watson’s lidocaine topical patch), and elevated the generic review activities to “Super Office” status.
You may also be interested in...
More FDASIA reorganizations at FDA; Key QbD elements expected in ANDA supplements.
Congress is on the verge of enacting important new incentives for antibiotic development. At the same time, a federal court ruling on Vancocin generic approvals underscores the importance of doing things the right way.
When it comes to the new biosimilar pathway, it’s the IND—not the BLA—that matters.